[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576271":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":51,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":10,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Santa Chiara Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"mCRPC treated with olaparib",null,"mCRPC patients who receive olaparib in daily clinical practice",[13],"Drug: Olaparib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Olaparib","Olaparib given according the clinical practice to BRCA positive mCRPC patients",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Orazio Caffo, MD","CONTACT","+390461902478","orazio.caffo@apss.tn.it",[27,41],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Sabrina Rossetti","RECRUITING","Naples","Italy","IT",{"type":34,"coordinates":35},"Point",[36,37],14.26811,40.85216,{"lat":37,"lon":36},[40],{"name":28,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":42,"status":29,"city":43,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"Orazio Caffo","Trento",{"type":34,"coordinates":45},[46,47],11.12108,46.06787,{"lat":47,"lon":46},[50],{"name":42,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":52,"investigatorFullName":42,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","MD","100576271","clinical-outcomes-of-use-of-olaparib-in-castration-resistant-prostate-cancer-100576271",false,"NCT06783127","Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer","Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study","COROS","Inclusion Criteria:\n\nBRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice\n\nExclusion Criteria:\n\nOlaparib treatment in a clinical trial","MALE",{"count":64,"type":65},3000,"ESTIMATED","OBSERVATIONAL","This is an observational, retrospective\u002Fprospective, multicenter study designed to define, overall survival, clinical outcomes and predictive\u002Fprognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.",[69,70,71],"Prostate Cancer","Castrate Resistant Prostate Cancer","BRCA Mutation","2025-02-07",{"date":74,"type":75},"2025-02-11","ACTUAL",{"date":77,"type":75},"2023-01-01",{"date":79,"type":65},"2026-12-31",{"name":5,"class":6},2]